14/11/2022
Possible solutions to improve the European regulatory procedures for clinical trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms
25/05/2021
EuropaBio welcomes the in-depth opinion of the European Group on Ethics on the uses of genome editing and thanks the Group for raising the awareness of a technology which will enable the development of many solutions for healthy people and planet.
29/04/2021
EuropaBio welcomes the in-depth opinion of the European Group on Ethics on the uses of genome editing and thanks the Group for raising the awareness of a technology which will enable the development of many solutions for healthy people and planet.
31/03/2021
EuropaBio welcomes the in-depth opinion of the European Group on Ethics on the uses of genome editing and thanks the Group for raising the awareness of a technology which will enable the development of many solutions for healthy people and planet.
12/03/2021
Advanced therapies have ground-breaking therapeutic potential, particularly in disease areas where there is an unmet medical need and available therapeutic options are absent or inadequate. These […]
30/11/2020
Call for more effective EU regulation of clinical trials with Advanced Therapy
Medicinal Products consisting of or containing Genetically Modified Organisms
19/10/2020
EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
24/09/2020
Genome editing is an advance in biological tools with the potential for a wide range of applications.
24/08/2020
This is a non-exhaustive list of over 200 genome-editing or viral vector related products and research projects, drawn from various resources and covering healthcare, industrial and agricultural biotech
20/05/2020
EuropaBio and its members strongly believe that genome editing will enable the development of many solutions to the grand challenges facing both people and planet. In medicine, genome editing offers the prospect of saving lives and tackling some of the most devastating genetic diseases.
30/04/2020
The 30th anniversary of World Haemophilia Day helps to illustrate the importance to support the bleeding disorders community. Read our interview with Amanda Bok, CEO of the European Haemophilia Consortium (EHC) & Co-Chair of EuropaBio's Patients BioForum.
28/04/2020
On the occasion of World PI Week we interviewed Johan Prevot, Executive Director of the International Patient Organisation for Primary Immunodeficiencies (IPOPI).
17/04/2020
On the occasion of World Haemophilia Day we had the pleasure to interview Dr. Ian Winburn, Global Medical Lead within Pfizer’s Rare Disease Business Unit.
17/04/2020
On the occassion of World Haemophilia Day, read a message from Paul Perreault, CEO of CSL Behring.
17/04/2020
During World Haemophilia Week, we caught up with Sobi's Head of Haematology, Philip Wood.
09/03/2020
To ensure the EU remains a leader in ATMP innovation, this paper outlines and elaborates EuropaBio’s position and policy recommendations to the European Commission across three key focus areas.
26/01/2020
A combination of antiviral therapy and genome editing has succeeded in removing the HIV virus from infected mice.